Aducanumab (BIIB037) showed significant time and dose dependent reduction of beta amyloid in the brain of AD patients
Neurimmune is a biopharmaceutical company dedicated to the development of innovative immunotherapeutics for human diseases. Its Reverse Translational Medicine™ platform generates recombinant human monoclonal antibodies with unique therapeutic properties. Together with target selectivity and high affinities these antibodies combine superior risk profiles with excellent efficacy.
Neurimmune has partnered four antibody programs with Biogen Idec. Antibody Aducanumab (BIIB037) for Alzheimer's disease is in late-stage Phase 1b clinical trials (PRIME). Therapeutic antibodies for Parkinson’s disease, tauopathies and fronto-temporal dementia are in preclinical stages.
Neurimmune’s program packages for amyotrophic lateral sclerosis, transthyretin amyloidosis and type-2 diabetes are validated with preclinical proof-of-concept. They are ready for partnering
